<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        292-24-18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ESBRIET 801 MG FILM COATED TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PIRFENIDONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        801
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        90
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        7342.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="DELPHARM MILANO SRI" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            DELPHARM MILANO SRI
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ROCHE
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AX05 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Esbriet contains the active substance pirfenidone and it is used for the treatment of mild to moderate Idiopathic Pulmonary Fibrosis (IPF) in adults.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>IPF is a condition in which the tissues in your lungs become swollen and scarred over time, and as a result makes it difficult to breathe deeply. This makes it hard for your lungs to work properly. Esbriet helps to reduce scarring and swelling in the lungs, and helps you breathe better.&nbsp;</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Do not take Esbriet&nbsp;</strong></p><p dir="ltr"><strong>● if you are allergic to pirfenidone or any of the other ingredients of this medicine (listed in section 6)</strong></p><p dir="ltr"><strong>● if you have previously experienced angioedema with pirfenidone, including symptoms such as swelling of the face, lips and/or tongue which may be associated with difficulty breathing or wheezing</strong></p><p dir="ltr"><strong>● if you are taking a medicine called fluvoxamine (used to treat depression and obsessive compulsive disorder [OCD])&nbsp;</strong></p><p dir="ltr"><strong>● if you have severe or end stage liver disease</strong></p><p dir="ltr"><strong>● if you have severe or end stage kidney disease requiring dialysis.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If any of the above affects you, do not take Esbriet. If you are unsure ask your doctor or pharmacist.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Warnings and precautions</strong></p><p dir="ltr"><strong>Talk to your doctor or pharmacist before taking Esbriet</strong></p><p dir="ltr"><strong>● You may become more sensitive to sunlight (photosensitivity reaction) when taking Esbriet. Avoid the sun (including sunlamps) whilst taking Esbriet. Wear sunblock daily and cover your arms, legs and head to reduce exposure to sunlight (see section&nbsp;4: Possible side effects).</strong></p><p dir="ltr"><strong>● You should not take other medicines, such as tetracycline antibiotics (such as doxycycline), which may make you more sensitive to sunlight.&nbsp;&nbsp;</strong></p><p dir="ltr"><strong>● You should tell your doctor if you suffer from mild to moderate liver problems.</strong></p><p dir="ltr"><strong>● You should stop smoking before and during treatment with Esbriet. Cigarette smoking can reduce the effect of Esbriet.</strong></p><p dir="ltr"><strong>● Esbriet may cause dizziness and tiredness. Be careful if you have to take part in activities where you have to be alert and co-ordinated.&nbsp;</strong></p><p dir="ltr"><strong>● Esbriet can cause weight loss. Your doctor will monitor your weight whilst you are taking this medicine.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>You will need a blood test before you start taking Esbriet and at monthly intervals for the first 6&nbsp;months and then every 3&nbsp;months thereafter whilst you are taking this medicine to check whether your liver is working properly. It is important that you have these regular blood tests for as long as you are taking Esbriet.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Children and adolescents</strong></p><p dir="ltr"><strong>Do not give Esbriet to children and adolescents under the age of 18.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Other medicines and Esbriet</strong></p><p dir="ltr"><strong>Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>This is especially important if you are taking the following medicines, as they may change the effect of Esbriet.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Medicines that may increase side effects of Esbriet:</strong></p><p dir="ltr"><strong>● enoxacin (a type of antibiotic)</strong></p><p dir="ltr"><strong>● ciprofloxacin (a type of antibiotic)</strong></p><p dir="ltr"><strong>● amiodarone (used to treat some types of heart disease)</strong></p><p dir="ltr"><strong>● propafenone (used to treat some types of heart disease)</strong></p><p dir="ltr"><strong>● fluvoxamine (used to treat depression and obsessive compulsive disorder (OCD)).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Medicines that may reduce how well Esbriet works:</strong></p><p dir="ltr"><strong>● omeprazole (used in the treatment of conditions such as indigestion, gastroesophageal reflux disease)</strong></p><p dir="ltr"><strong>● rifampicin (a type of antibiotic).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Esbriet with food and drink</strong></p><p dir="ltr"><strong>Do not drink grapefruit juice whilst taking this medicine. Grapefruit may prevent Esbriet from working properly.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pregnancy and breast-feeding</strong></p><p dir="ltr"><strong>As a precautionary measure, it is preferable to avoid the use of Esbriet if you are pregnant, planning to become pregnant, or think you might be pregnant as the potential risks to the unborn child are unknown.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If you are breast-feeding or plan to breast-feed speak to your doctor or pharmacist before taking Esbriet. As it is unknown whether Esbriet passes into breast milk, your doctor will discuss the risks and benefits of taking this medicine while breast-feeding if you decide to do so.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Driving and using machines</strong></p><p dir="ltr"><strong>Do not drive or use machines if you feel dizzy or tired after taking Esbriet.&nbsp;</strong></p><p><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Treatment with Esbriet should be started and overseen by a specialist doctor experienced in the diagnosis and treatment of IPF.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.&nbsp;&nbsp;</strong></p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Your medicine will usually be given to you in increasing doses as follows:</strong></p><p dir="ltr"><strong>● for the first 7&nbsp;days take a dose of 267 mg (1 yellow tablet), 3&nbsp;times a day with food (a total of 801&nbsp;mg/day)</strong></p><p dir="ltr"><strong>● from day 8&nbsp;to 14&nbsp;take a dose of 534 mg (2 yellow tablets or 1 orange tablet), 3&nbsp;times a day with food (a total of 1,602&nbsp;mg/day)&nbsp;</strong></p><p dir="ltr"><strong>● from day 15&nbsp;onwards (maintenance), take a dose of 801 mg (3 yellow tablets or 1 brown tablet), 3&nbsp;times a day with food (a total of 2,403&nbsp;mg/day).&nbsp;&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The recommended maintenance daily dose of Esbriet is 801 mg (3 yellow tablets or 1 brown tablet) three times a day with food, for a total of 2403 mg/day.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Swallow the tablets whole with a drink of water, during or after a meal to reduce the risk of side&nbsp;effects such as nausea (feeling sick) and dizziness. If symptoms continue, see your doctor.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Dose reduction due to side effects</strong></p><p dir="ltr"><strong>Your doctor may reduce your dose if you suffer from side effects such as, stomach problems, any skin reactions to sunlight or sun lamps, or significant changes to your liver enzymes.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If you take more Esbriet than you should&nbsp;</strong></p><p dir="ltr"><strong>Contact your doctor, pharmacist or nearest hospital casualty department immediately if you have taken more tablets than you should, and take your medicine with you.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If you forget to take Esbriet&nbsp;</strong></p><p dir="ltr"><strong>If you forget a dose, take it as soon as you remember. Do not take a double dose to make up for a forgotten dose. Each dose should be separated by at least 3 hours. Do not take more tablets each day than your prescribed daily dose.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If you stop taking Esbriet</strong></p><p dir="ltr"><strong>In some situations, your doctor may advise you to stop taking Esbriet. If for any reason you have to stop taking Esbriet for more than 14&nbsp;consecutive days, your doctor will restart your treatment with a dose of&nbsp;267 mg 3&nbsp;times a day, gradually increasing this to a dose of 801 mg 3&nbsp;times a day.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Like all medicines, this medicine can cause side effects, although not everybody gets them.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Stop taking Esbriet and tell your doctor immediately</strong></p><p dir="ltr"><strong>● If you experience swelling of the face, lips and/or tongue, difficulty breathing or wheezing, which are signs of angioedema, a serious allergic reaction. This is an uncommon side effect.</strong></p><p dir="ltr"><strong>● If you experience yellowing of the eyes or skin, or dark urine, potentially accompanied by itching of the skin, which are signs of abnormal liver function tests. These are rare side effects.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Other side effects may include</strong></p><p dir="ltr"><strong>Talk to your doctor if you get any side effects.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Very common side effects (may affect more than 1 in 10 people):&nbsp;</strong></p><p dir="ltr"><strong>● skin reactions after going out in the sun or using sunlamps</strong></p><p dir="ltr"><strong>● feeling sick (nausea)</strong></p><p dir="ltr"><strong>● tiredness&nbsp;</strong></p><p dir="ltr"><strong>● diarrhoea</strong></p><p dir="ltr"><strong>● indigestion or stomach upset</strong></p><p dir="ltr"><strong>● loss of appetite</strong></p><p dir="ltr"><strong>● headache.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Common side effects (may affect up to 1 in 10 people):</strong></p><p dir="ltr"><strong>● infections of the throat or the airways going into the lungs and/or sinusitis&nbsp;&nbsp;</strong></p><p dir="ltr"><strong>● bladder infections&nbsp;</strong></p><p dir="ltr"><strong>● weight loss&nbsp;</strong></p><p dir="ltr"><strong>● difficulty sleeping&nbsp;</strong></p><p dir="ltr"><strong>● dizziness&nbsp;</strong></p><p dir="ltr"><strong>● feeling sleepy</strong></p><p dir="ltr"><strong>● changes in taste</strong></p><p dir="ltr"><strong>● hot flushes&nbsp;</strong></p><p dir="ltr"><strong>● shortness of breath</strong></p><p dir="ltr"><strong>● cough&nbsp;</strong></p><p dir="ltr"><strong>● stomach problems such as acid reflux, vomiting, feeling bloated, abdominal pain and discomfort, heart burn, feeling constipated and passing wind</strong></p><p dir="ltr"><strong>● blood tests may show increased levels of liver enzymes&nbsp;</strong></p><p dir="ltr"><strong>● skin problems such as itchy skin, skin redness or red skin, dry skin, skin rash&nbsp;</strong></p><p dir="ltr"><strong>● muscle pain, aching joints/joint pains&nbsp;</strong></p><p dir="ltr"><strong>● feeling weak or feeling low in energy&nbsp;</strong></p><p dir="ltr"><strong>● chest pain&nbsp;</strong></p><p dir="ltr"><strong>● sunburn.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Rare side effects (may affect up to 1 in 1,000 people):</strong></p><p dir="ltr"><strong>● blood tests may show decrease in white blood cells.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Reporting of side effects&nbsp;</strong></p><p dir="ltr"><strong>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly. By reporting side effects you can help provide more information on the safety of this medicine.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Keep this medicine out of the sight and reach of children.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Do not use this medicine after the expiry date which is stated on the bottle label, blister&nbsp; and carton after EXP. The expiry date refers to the last day of that month.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>This medicine does not require any special storage conditions.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</strong></p><p><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>267 mg tablet</strong></p><p dir="ltr"><strong>The active substance is pirfenidone. Each film-coated tablet contains 267&nbsp;mg of pirfenidone.&nbsp;</strong></p><p dir="ltr"><strong>The other ingredients are: microcrystalline cellulose, croscarmellose sodium, povidone K30, colloidal anhydrous silica, magnesium stearate&nbsp;</strong></p><p dir="ltr"><strong>The film coat consists of: polyvinyl alcohol, titanium dioxide (E171), macrogol 3350, talc, iron oxide yellow (E172)</strong></p><p>&nbsp;</p><p dir="ltr"><strong>534 mg tablet</strong></p><p dir="ltr"><strong>The active substance is pirfenidone. Each film-coated tablet contains 534 mg of pirfenidone.&nbsp;</strong></p><p dir="ltr"><strong>The other ingredients are: microcrystalline cellulose, croscarmellose sodium, povidone K30, colloidal anhydrous silica, magnesium stearate&nbsp;</strong></p><p dir="ltr"><strong>The film coat consists of: polyvinyl alcohol, titanium dioxide (E171), macrogol 3350, talc, iron oxide yellow (E172) and iron oxide red (E172)</strong></p><p>&nbsp;</p><p dir="ltr"><strong>801 mg tablet</strong></p><p dir="ltr"><strong>The active substance is pirfenidone. Each film-coated tablet contains 801 mg of pirfenidone.&nbsp;</strong></p><p dir="ltr"><strong>The other ingredients are: microcrystalline cellulose, croscarmellose sodium, povidone K30, colloidal anhydrous silica, magnesium stearate&nbsp;</strong></p><p dir="ltr"><strong>The film coat consists of: polyvinyl alcohol, titanium dioxide (E171), macrogol 3350, talc, iron oxide red (E172) and iron oxide black (E172)</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                267 mg tablet
Esbriet 267 mg film-coated tablets are yellow, oval, biconvex film-coated tablets, debossed with “PFD”.
The bottle packs contain one bottle containing 21 tablets, two bottles each containing 21 tablets (42 tablets in total), one bottle containing 90 tablets or two bottles each containing 90 tablets (180 tablets in total). 
The blister packs contain 21, 42, 84 or 168 film-coated tablets and the multipacks contain 63 (2-week treatment initiation pack 21+42) or 252 (continuation pack 3x84) film-coated tablets. 
534 mg tablet
Esbriet 534 mg film-coated tablets are orange, oval, biconvex film-coated tablets, debossed with “PFD”.
The bottle packs contain either one bottle containing 21 tablets or one bottle containing 90 tablets. 

801 mg tablet
Esbriet 801 mg film-coated tablets are brown, oval, biconvex film-coated tablets, debossed with “PFD”.
The bottle pack contains one bottle containing 90 tablets. 
The blisters pack contains 84 film-coated tablets and the multipack contains 252 (continuation pack 3x84) film-coated tablets. 

The 801 mg blisters strips are each marked with the following symbols as a reminder to take a dose three times a day:
 (sunrise; morning dose)  (sun; daytime dose) and (moon; evening dose).

Not all pack sizes may be marketed.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>F. Hoffmann-La Roche Ltd,</strong></p><p dir="ltr"><strong>Grenzacherstrasse 124,&nbsp;</strong></p><p dir="ltr"><strong>CH-4070 Basel,&nbsp;</strong></p><p dir="ltr"><strong>Switzerland.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in April 2017.


To reports any side effect(s):

Saudi Arabia:

The National Pharmacovigilance and Drug Safety Centre (NPC)
Fax: +966-11-205-7662
Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.
Toll free phone: 8002490000
E-mail: npc.drug@sfda.gov.sa
Website: www.sfda.gov.sa/npc

 Other GCC States:
Please contact the relevant competent authority.
 


Council of Arab Health Ministers

This is a Medicament
Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you. 
Follow strictly the doctor’s prescription, the method of use and the instructions of the pharmacist who sold the medicament. 
The doctor and the pharmacist are the experts in medicines, their benefits and risks. 
Do not by yourself interrupt the period of treatment prescribed for you. 
Do not repeat the same prescription without consulting your doctor. 
Keep all medicaments out of reach of children. 

Council of Arab Health Ministers
Union of Arab Pharmacists



            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="rtl"><strong>إسبريت يحتوي على المادة الفعالة بيرفينيدون ويستخدم لعلاج التليف الرئوي مجهول السبب الخفيف إلى المتوسط عند البالغين.</strong></p><p dir="rtl"><strong>والتليف الرئوي مجهول السبب هو حالة تصبح فيها أنسجة الرئتين متورمة مع ظهور الندبات مع مرور الوقت، ةنتيجة لذلك يصبح من الصعب التنفس بعمق.&nbsp; وهذا يجعل من الصعب على الرئتين العمل بشكل صحيح.&nbsp; ويساعد إسبريت على الحد من الندبات والتورم في الرئتين ويساعدك على التنفس بشكل أفضل.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>يجب عليك عدم تناول دواء إسبريت في الحالات التالية:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>إذا كانت لديك حساسية لمادة بيرفينيدون أو أي من المكونات الأخرى لهذا الدواء (المذكورة في الجزء السادس).</strong></p></li><li dir="rtl"><p dir="rtl"><strong>إذا حدث لديك وذمة وعائية من قبل مع البيرفينيدون، ويشمل ذلك الأعراض مثل التورم في الوجه و/أو الشفتين و/أو اللسان والذي قد يرتبط بصعوبة التنفس أو الصفير.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>في حالة تناولك دواء فلوفوكسامين (المستخدم لعلاج الاكتئاب واضطراب الوسواس القهري).</strong></p></li><li dir="rtl"><p dir="rtl"><strong>إذا كنت تعاني من مرض حاد في الكبد أو في مرحلة متأخرة.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>إذا كنت تعاني من مرض حاد في الكلى أو في مرحلة متأخرة يتطلب غسيل الكلى.</strong></p></li></ul><p dir="rtl"><strong>في حالة تأثرك بأي مما سبق، لا تتناول إسبريت.&nbsp; وفي حالة عدم تأكدك، يجب عليك استشارة الطبيب أو الصيدلي.</strong></p><p dir="rtl"><strong>التحذيرات والاحتياطات:</strong></p><p dir="rtl"><strong>تحدث إلى الطبيب أو الممرضة قبل تناول إسبريت في الحالات التالية:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>في حالة وجود احتمال لأن تصبح أكثر حساسية لضوء الشمس (ارتكاس الحساسية للضوء) أثناء تناول إسبريت.&nbsp; تجنب الشمس (ويشمل ذلك المصابيح الشمسية) أثناء تناول إسبريت.&nbsp; يجب عليك استخدام حاجز الشمس يوميا وتغطية الذراعين والرجلين والرأس لتقليل التعرض لضوء الشمس (انظر الجزء الرابع:&nbsp; الآثار الجانبية المحتملة).</strong></p></li><li dir="rtl"><p dir="rtl"><strong>يجب عليك عدم تناول أدوية أخرى مثل المضادات الحيوية التي تدخل فيها مادة تتراسيكلين (مثل دوكسيسيكلين) التي تجعلك أكثر حساسية لضوء الشمس.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>يجب عليك أن تخبر طبيبك إذا كنت تعاني من مشكلات في الكبد خفيفة إلى متوسطة.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>يجب عليك أن تتوقف عن التدخين قبل وأثناء العلاج باستخدام إسبريت.&nbsp; فتدخين السجائر من الممكن أن يقلل من تأثير الدواء.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>إسبريت دواء قد يسبب الدوار والتعب.&nbsp; كن حريضا عند المشاركة في الأنشطة التي تتطلب منك اليقظة والتنسيق.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>إسبريت دواء قد يسبب فقدان الوزن.&nbsp; وسوف يراقب طبيبك وزنك أثناء تناول هذا الدواء.</strong></p></li></ul><p dir="rtl"><strong>سوف تحتاج إلى إجراء تحليل دم قبل البدء في تناول إسبريت وعلى فترات شهرية لأول ستة أشهر ثم كل ثلاثة أشهر بعد ذلك أثناء تناول هذا الدواء للتأكد من كفاءة الكبد.&nbsp; ومن المهم إجراء هذه التحاليل المنتظمة طوال فترة تناول هذا الدواء.</strong></p><p dir="rtl"><strong>الأطفال والمراهقون:</strong></p><p dir="rtl"><strong>لا تعطي إسبريت للأطفال والمراهقين تحت 18 عام.</strong></p><p dir="rtl"><strong>الأدوية الأخرى وإسبريت:</strong></p><p dir="rtl"><strong>أخبر طبيبك أو الصيدلي في حالة تنازلك أو تناولت مؤخرا أو ربما تتناول أي أدوية أخرى.</strong></p><p dir="rtl"><strong>وهذا الأمر مهم بصورة خاصة في حالة تناولك للأدوية التالية حيث أنها من الممكن أن تغير من تأثير إسبريت.</strong></p><p dir="rtl"><strong>الأدوية التي قد تزيد من الآثار الجانبية لإسبريت:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>إينوكساسين (نوع من المضاد الحيوي)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>سيبروفلوكساسين (نوع من المضاد الحيوي)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>أميودارون (يستخدم لعلاج بعض أمراض القلب)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>بروبافينون (يستخد لعلاج بعض أمراض القلب)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>فلوفوكسامين (يستخدم لعلاج الاكتئاب واضطراب الوسواس القهري)</strong></p></li></ul><p dir="rtl"><strong>الأدوية التي قد تقلل من كفاءة عمل إسبريت:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>أوميبازول (يستخدم في علاج بعض الحالات مثل عسر الهضم وارتجاع المرىء</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ريفامبيسين (نوع من المضاد الحيوي)</strong></p></li></ul><p dir="rtl"><strong>إسبريت مع الطعام والشراب:</strong></p><p dir="rtl"><strong>لا تتناول عصير الجريب فروت أثناء تناول هذا الدواء فقد يمنع إسبريت من العمل بكفاءة.</strong></p><p dir="rtl"><strong>الحمل والإرضاع:</strong></p><p dir="rtl"><strong>كإجراء احترازي، من المفضل تجنب استخدام إسبريت مع الحمل أو عند التخطيط للحمل أو الاعتقاد بحدوث الحمل نظرا لأن المخاطر المحتملة على الجنين غير معروفة.</strong></p><p dir="rtl"><strong>وفي حالة الإرضاع أو التخطيط للإرضاع، يجب التحدث إلى الطبيب أو الصيدلي قبل تناول إسبريت حيث أنه من غير المعروف ما إذا كان إسبريت يمر عبر حليب الثدي أم لا، وسوف يناقش طبيبك المخاطر والفوائد المتعلقة بتناول هذا الدواء أثناء الإرضاع في حالة قرارك الاستمرار في الإرضاع.</strong></p><p dir="rtl"><strong>القيادة واستخدام الآلات:</strong></p><p dir="rtl"><strong>يجب عليك عدم القيادة أو استخدام الآلات إذا شعرت بالدوار أو التعب بعد تناول إسبريت.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>يجب بدء العلاج باستخدام إسبريت والإشراف عليه من قبل الطبيب المختص الذي لديه الخبرة في تشخيص وعلاج التليف الرئوي مجهول السبب.</strong></p><p dir="rtl"><strong>يجب تناول هذا الدواء دائما طبقا لتعليمات الطبيب أو الصيدلي.&nbsp; تحقق من الطبيب أو الصيدلي عن المعلومات التي بحاجة إلى التأكد منها.</strong></p><p dir="rtl"><strong>يتم دائما إعطاؤك الدواء مع زيادة الجرعات تدريجيا كالتالي:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>أول سبعة أيام تناول جرعة مقدارها 267 مج (1 قرص أصفر) ثلاث مرات يوميا مع الأكل (بإجمالي 801 مج / اليوم).</strong></p></li><li dir="rtl"><p dir="rtl"><strong>من اليوم الثامن وحتى اليوم الرابع عشر تناول جرعة مقدارها 534 مج (2 قرص أصفر أو 1 قرص برتقالي) ثلاث مرات يوميا مع الأكل (بإجمالي 1,602 مج / اليوم).</strong></p></li><li dir="rtl"><p dir="rtl"><strong>من اليوم الخامس عشر فصاعدا (باستمرار)، تناول جرعة مقدارها 801 مج (3 قرص أصفر أو 1 قرص بني) ثلاث مرات يوميا مع الأكل (بإجمالي 2,403 مج / اليوم).</strong></p></li></ul><p dir="rtl"><strong>الجرعة اليومية المستمرة الموصي بها من إسبريت هي 801 مج (3 قرص أصفر أو 1 قرص بني) ثلاث مرات يوميا مع الأكل ، بإجمالي 2403 مج / اليوم.</strong></p><p dir="rtl"><strong>ابتلع الأقراص بالكامل مع شرب الماء أثناء أو بعد الأكل لتقليل خطر الآثار الجانبية مثل الغثيان (الشعور بالإعياء) والدوار.&nbsp; وفي حالة استمرار الأعراض يجب عليك الرجوع إلى الطبيب.</strong></p><p dir="rtl"><strong>تقليل الجرعة بسبب الآثار الجانبية:</strong></p><p dir="rtl"><strong>قد يقرر طبيبك تقليل الجرعة إذا كنت تعاني من الآثار الجانبية مثل مشكلات المعدة وأي ارتكاسات للجلد نتيجة لضوء الشمس أو المصابيح الشمسية أو تغيرات كبيرة في إنزيمات الكبد.</strong></p><p dir="rtl"><strong>في حالة تناول جرعة زائدة من إسبريت:</strong></p><p dir="rtl"><strong>اتصل بطبيبك أو الصيدلي أو أقرب مستشفى على الفور في حالة تناول جرعة زائدة من إسبريت وخذ الدواء معك.</strong></p><p dir="rtl"><strong>في حالة نسيان تناول جرعة إسبريت:</strong></p><p dir="rtl"><strong>في حالة نسيان تناول جرعة إسبريت، خذ الجرعة في أقرب وقت ممكن بمجرد تذكرك للدواء.&nbsp; لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسية.&nbsp; ويجب أن يمر ثلاث ساعات بين الجرعة والجرعة التالية.&nbsp; لا تأخذ جرعة أكثر من الجرعة اليومية الموصوفة لك.</strong></p><p dir="rtl"><strong>في حالة التوقف عن تناول إسبريت:</strong></p><p dir="rtl"><strong>في بعض المواقف، قد ينصحك الطبيب للتوقف عن تناول إسبريت.&nbsp; وفي حالة اضطرارك التوقف عن تناول إسبريت لأي سبب من الأسباب، لأكثر من 14 يوم متتالية، فسوف يعيد طبيبك بدء العلاج بجرعة مقدارها 267 مج ثلاث مرات يوميا تزداد تدريجيا إلى جرعة مقدارها 801 مج ثلاث مرات يوميا.</strong></p><p dir="rtl"><strong>اسأل طبيبك أو الصيدلي في حالة وجود أي تساؤلات أخرى عن استخدام هذا الدواء.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>هذا العقار مثله مثل أي دواء آخر من الممكن أن يسبب آثار جانبية ولكنها لا تحدث لجميع الأشخاص.</strong></p><p dir="rtl"><strong>توقف عن تناول إسبريت وأخبر طبيبك على الفور في الحالات التالية:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>إذا كنت تعاني من التورم في الوجه و/أو الشفتين و/أو اللسان أو صعوبة في التنفس أو الصفير، فكل هذه أعراض الوذمة الوعائية وهي عبارة عن ارتكاس حساسية خطير.&nbsp; وهذا أثر جانبي غير شائع.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>إذا كنت تعاني من اصفرار العينين أو الجلد أو البول الغامق الذي قد يكون مصحوبا بالحكة في الجلد، وهذه أعراض الاعتلال الوظيفي للكبد.&nbsp; وهذه الآثار الجانبية تكون نادرة الحدوث.</strong></p></li></ul><p dir="rtl"><strong>وقد تشمل الآثار الجانبية الأخرى:</strong></p><p dir="rtl"><strong>تحدث إلى طبيبك عند حدوث أي من الآثار الجانبية.</strong></p><p dir="rtl"><strong>آثار جانبية شائعة جدا (قد تحدث لأكثر من شخص من بين كل عشرة أشخاص):</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>ارتكاسات الجلد بعد الخروج في الشمس أو استخدام المصابيح الشمسية.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الشعور بالإعياء (الغثيان)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>التعب</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الإسهال</strong></p></li><li dir="rtl"><p dir="rtl"><strong>عسر الهضم</strong></p></li><li dir="rtl"><p dir="rtl"><strong>فقدان الشهية</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الصداع</strong></p></li></ul><p dir="rtl"><strong>آثار جانبية شائعة (قد تحدث لشخص واحد من بين كل عشرة أشخاص):</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>عدوى الحلق أو التنفس داخل الرئة و/أو الجيوب الأنفية</strong></p></li><li dir="rtl"><p dir="rtl"><strong>عدوى المثانة البولية</strong></p></li><li dir="rtl"><p dir="rtl"><strong>فقدان الوزن</strong></p></li><li dir="rtl"><p dir="rtl"><strong>صعوبة النوم</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الدوار</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الشعور بالنعاس</strong></p></li><li dir="rtl"><p dir="rtl"><strong>التغير في المذاق</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الاحمرار والسخونة</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ضيق التنفس</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الكحة</strong></p></li><li dir="rtl"><p dir="rtl"><strong>مشكلات المعدة مثل الحموضة لقىء والشعور بالانتفاخ، الألم في البطن، حرقة المعدة، الشعور بالإمساك والغازات</strong></p></li><li dir="rtl"><p dir="rtl"><strong>تحاليل الدم قد تظهر مستويات عالية من إنزيمات الكبد</strong></p></li><li dir="rtl"><p dir="rtl"><strong>مشكلات الجلد مثل الحكة والاحمرار أو الطفح الجلدي&nbsp;</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الألم في العضلات والمفاصل&nbsp;</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الشعور بالضعف أو انخفاض الطاقة</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الألم في الصدر</strong></p></li><li dir="rtl"><p dir="rtl"><strong>حرقة الشمس</strong></p></li></ul><p dir="rtl"><strong>آثار جانبية نادرة الحدوث (قد تؤثر في شخص واحد من بين كل 1000 شخص):</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>تحاليل الدم قد تظهر زيادة في خلايا الدم البيضاء</strong></p></li></ul><p dir="rtl"><strong>تسجيل الآثار الجانبية:</strong></p><p dir="rtl"><strong>في حالة حدوث أي من الآثار الجانبية، تحدث إلى الطبيب أو الصيدلي.&nbsp; وهذا يشمل أية آثار جانبية غير مذكورة في هذه النشرة.&nbsp; ويمكنك الإبلاغ عن الآثار الجانبية بصورة مباشرة.&nbsp; ومن خلال الإبلاغ عن الآثار الجانبية يمكنك المساعدة في إعطاء المزيد من المعلومات من سلامة هذا الدواء.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>يحفظ هذا الدواء بعيدا عن متناول الأطفال.</strong></p><p dir="rtl"><strong>لا يستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الخارجية.&nbsp; ويشير تاريخ الانتهاء إلى اليوم الأخير من الشهر.</strong></p><p dir="rtl"><strong>هذا الدواء لا يحتاج إلى شروط تخزين خاصة.</strong></p><p dir="rtl"><strong>يجب عدم التخلص من الدواء في مياه الصرف أو المخلفات المنزلية.&nbsp; اسألي الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مستخدمة.&nbsp; وهذه التدابير سوف تساعدك على حماية البيئة.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>يحتوي عقار إسبريت على:</strong></p><p dir="rtl"><strong>أقراص 267 مج:</strong></p><p dir="rtl"><strong>المادة الفعالة بيرفينيدون.&nbsp; يحتوي كل قرص مغلف على 267 مج من المادة الفعالة بيرفينيدون.&nbsp; والعناصر الأخرى هي:&nbsp; ميكروكريستالين سيلولوز، كروسكارميلوز صوديوم، بوفيدون K30، كولويدال أنهيدروس سيليكا، سترات الماغنسيوم.</strong></p><p dir="rtl"><strong>وتتكون مادة الغلاف من كحول بوليفينيل، ثاني أكسيد التيتانيوم (E171)، ماكروجول 3350، تلك، أكسيد الحديد الأصفر (E172).</strong></p><p dir="rtl"><strong>أقراص 534 مج:</strong></p><p dir="rtl"><strong>المادة الفعالة بيرفينيدون.&nbsp; يحتوي كل قرص مغلف على 534 مج من المادة الفعالة بيرفينيدون.&nbsp; والعناصر الأخرى هي:&nbsp; ميكروكريستالين سيلولوز، كروسكارميلوز صوديوم، بوفيدون K30، كولويدال أنهيدروس سيليكا، سترات الماغنسيوم.</strong></p><p dir="rtl"><strong>وتتكون مادة الغلاف من كحول بوليفينيل، ثاني أكسيد التيتانيوم (E171)، ماكروجول 3350، تلك، أكسيد الحديد الأصفر (E172)، أكسيد الحديد الأحمر (E172).</strong></p><p dir="rtl"><strong>أقراص 801 مج:</strong></p><p dir="rtl"><strong>المادة الفعالة بيرفينيدون.&nbsp; يحتوي كل قرص مغلف على 801 مج من المادة الفعالة بيرفينيدون.&nbsp; والعناصر الأخرى هي:&nbsp; ميكروكريستالين سيلولوز، كروسكارميلوز صوديوم، بوفيدون K30، كولويدال أنهيدروس سيليكا، سترات الماغنسيوم.</strong></p><p dir="rtl"><strong>وتتكون مادة الغلاف من كحول بوليفينيل، ثاني أكسيد التيتانيوم (E171)، ماكروجول 3350، تلك، أكسيد الحديد الأحمر (E172)، أكسيد الحديد الأسود (E172).</strong></p><p dir="rtl">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>شكل عقار إسبريت ومحتويات العبوة:</strong></p><p dir="rtl"><strong>أقراص 267 مج:</strong></p><p dir="rtl"><strong>إسبريت 267 مج أقراص مغلفة هي عبارة عن أقراص صفراء بيضاوية مغلفة محدبة الوجهين مختوم عليها &quot;PFD&quot;.</strong></p><p dir="rtl"><strong>تحتوي عبوة الزجاجة على زجاجة واحدة تتكون من 21 قرص، أو زجاجتين تحتوي كل منهما على 21 قرص (بإجمالي 42 قرص)، أو زجاجة واحدة تحتوي على 90 قرص، أو زجاجتين تحتوي كل منهما على 90 قرص (بإجمالي 180 قرص).</strong></p><p dir="rtl"><strong>وتحتوي عبوات الشرائط على 21 أو 42 أو 84 أو 168 قرص مغلف، وتحتوي العبوات المتعددة على 63 (عبوة بدء العلاج لمدة أسبوعين 21 + 42) أو 252 (عبوة مستمرة 3 * 84) أقراص مغلفة.</strong></p><p dir="rtl"><strong>أقراص 534 مج:</strong></p><p dir="rtl"><strong>إسبريت 534 مج أقراص مغلفة هي عبارة عن أقراص برتقالية بيضاوية مغلفة محدبة الوجهين مختوم عليها &quot;PFD&quot;.</strong></p><p dir="rtl"><strong>تحتوي عبوة الزجاجة على إما زجاجة واحدة تحتوي على 21 قرص أو زجاجة واحدة تحتوي على 90 قرص.</strong></p><p dir="rtl"><strong>أقراص 801 مج:</strong></p><p dir="rtl"><strong>إسبريت 801 مج أقراص مغلفة هي عبارة عن أقراص بنية بيضاوية مغلفة محدبة الوجهين مختوم عليها &quot;PFD&quot;.</strong></p><p dir="rtl"><strong>تحتوي عبوة الزجاجة على زجاجة واحدة تتكون من 90 قرص.</strong></p><p dir="rtl"><strong>وتحتوي عبوة الشرائط على 84 قرص مغلف، وتحتوي العبوات المتعددة على 252 (عبوة مستمرة 3 * 84) أقراص مغلفة.</strong></p><p dir="rtl"><strong>عبوات الشرائط للأقراص 801 مج عليها علامات بالرموز التالية للتذكرة بأخذ الجرعة ثلاث مرات يوميا:</strong></p><p dir="rtl"><strong><img width="44" height="29" src="https://lh3.googleusercontent.com/FYK11AM6QBrP9BFcTJ3mChHJZal2VHYIXUrqMDP61HJNApiayLciW5Smg3lzYiWt_BdUfJXdrHJMZ52BJp6a6wt5AzOvxPLQEesO4Qni22N0OYg6klzyglAGA6RFISmt6ZF3gOk" /> جرعة الصباح عند شروق الشمس</strong></p><p dir="rtl"><strong><img width="39" height="39" src="https://lh3.googleusercontent.com/bqlWM6Qg7YyOKw16SUYCBvCi4EF-EBD8dEeJ3Ft8-83vxF0ok-Dj5uJscbGhMYuR4lauOOgf4Cc5g4jYq0ptXTqWF4_zbHURTt69UbIQcJqKKQZs9Lbh2AhWgtgKamDHFPieB6o" /> جرعة الظهيرة</strong></p><p dir="rtl"><strong><img width="31" height="38" src="https://lh5.googleusercontent.com/wh0DxooOCTkTwZYE-lGvVOdP8gsB18yeRKpm3dfQ09FbYxSGBUcfjaO9TCgA0zdjkjpCbYVjNDoY_Jhzd5KK45M2Ad3jmuR4I8HOmpl-YZn9VJyeaQ89EBhrsWD5eCTamz9EAhg" /> جرعة المساء</strong></p><p dir="rtl"><strong>ولا تحتوي جميع أحجام العبوات على هذه العلامات</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>إف. هوفمان &ndash; لا روش المحدودة،</strong></p><p dir="rtl"><strong>124 جرينزاشيرستراس، سي إتش &ndash; 4070 بازل، سويسرا.</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            آخر تحديث لهذه النشرة بتاريخ أبريل 2017.
لتسجيل أي آثار جانبية:
المملكة العربية السعودية:
المركز الوطني للتيقظ والسلامة الدوائية (إن بي سي)
فاكس:  7662-205-11-966+
هاتف:  2038222-11-966+ داخلي:  2317 – 2356 – 2353 – 2354 – 2334 – 2340
الهاتف المجاني:  8002490000
البريد الإلكتروني:  npc.drug@sfda.gov.sa
الموقع على الإنترنت:  www.sfda.gov.sa/npc 

دول الخليج الأخرى:
يرجى الاتصال بالجهة المختصة.
مجلس وزراء الصحة العرب:
هذا الدواء:
هذا الدواء منتج يؤثر على صحتك واستهلاكه بطريقة مخالفة للتعليمات يعرض حياتك للخطر.
اتبع إرشادات الطبيب وطريقة الاستخدام وتعليمات الصيدلي الذي باع لك هذا الدواء.
الطبيب والصيدلي هم خبراء في الأدوية وفوائدها ومخاطرها.
لا تتوقف من تلقاء نفسك عن العلاج الموصوف لك.
لا تكرر نفس الوصفة الطبية من تلقاء نفسك دون استشارة الطبيب.
تحفظ جميع الأدوية بعيدا عن متناول الأطفال.

مجلس وزراء الصحة العرب
اتحاد الصيادلة العرب

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Esbriet 267 mg film-coated tablets
Esbriet 534 mg film-coated tablets
Esbriet 801 mg film-coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 267 mg pirfenidone.
Each film-coated tablet contains 534 mg pirfenidone.
Each film-coated tablet contains 801 mg pirfenidone.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).

Esbriet 267 mg film-coated tablets are yellow, oval, approximately 1.3 x 0.6. cm biconvex film-coated tablets, debossed with “PFD”. 
Esbriet 534 mg film-coated tablets are orange, oval, approximately 1.6 x 0.8 cm biconvex film-coated tablets, debossed with “PFD”. 
Esbriet 801 mg film-coated tablets are brown, oval, approximately 2 x 0.9 cm biconvex film-coated tablets, debossed with “PFD”. 


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Esbriet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF).</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Treatment with Esbriet should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of IPF.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Posology&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Adults</strong></p><p dir="ltr"><strong>Upon initiating treatment, the dose should be titrated to the recommended daily dose of 2403 mg/day over a 14day period as follows:</strong></p><p>&nbsp;</p><p dir="ltr"><strong>● Days 1 to 7: a dose of 267 mg administered three times a day (801&nbsp;mg/day)&nbsp;</strong></p><p dir="ltr"><strong>● Days 8 to 14: a dose of 534 mg administered three times a day (1602&nbsp;mg/day)&nbsp;</strong></p><p dir="ltr"><strong>● Day 15 onward: a dose of 801 mg administered three times a day (2403&nbsp;mg/day)&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The recommended maintenance daily dose of Esbriet is 801 mg three times a day with food for a total of 2403&nbsp;mg/day.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Doses above 2403&nbsp;mg/day are not recommended for any patient (see section 4.9).&nbsp;&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients who miss 14 consecutive days or more of Esbriet treatment should re-initiate therapy by undergoing the initial 2week titration regimen up to the recommended daily dose.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>For treatment interruption of less than 14&nbsp;consecutive days, the dose can be resumed at the previous recommended daily dose without titration.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Dose adjustments and other considerations for safe use</strong></p><p dir="ltr"><strong>Gastrointestinal events:&nbsp; In patients who experience intolerance to therapy due to gastrointestinal undesirable effects, patients should be reminded to take the medicinal product with food. If symptoms persist, the dose of pirfenidone may be reduced to 267&nbsp;mg &ndash; 534&nbsp;mg, two to three times a day with food with reescalation to the recommended daily dose as tolerated. If symptoms continue, patients may be instructed to interrupt treatment for one to two&nbsp;weeks to allow symptoms to resolve.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Photosensitivity reaction or rash:&nbsp; Patients who experience a mild to moderate photosensitivity reaction or rash should be reminded to use a sunblock daily and avoid exposure to the sun (see section 4.4). The dose of pirfenidone may be reduced to 801 mg each day (267 mg three times a day). If the rash persists after 7&nbsp;days, Esbriet should be discontinued for 15&nbsp;days, with reescalation to the recommended daily dose in the same manner as the dose escalation period.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients who experience severe photosensitivity reaction or rash should be instructed to interrupt the dose and to seek medical advice (see section 4.4). Once the rash has resolved, Esbriet may be reintroduced and reescalated up to the recommended daily dose at the discretion of the physician.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Hepatic function:&nbsp; In the event of significant elevation of alanine and/or aspartate aminotransferases (ALT/AST) with or without bilirubin elevation, the dose of pirfenidone should be adjusted or treatment discontinued according to the guidelines listed in section 4.4.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Special populations</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Elderly&nbsp;&nbsp;</strong></p><p dir="ltr"><strong>No dose adjustment is necessary in patients 65 years and older (see section 5.2).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Hepatic impairment&nbsp;&nbsp;</strong></p><p dir="ltr"><strong>No dose adjustment is necessary in patients with mild to moderate hepatic impairment (i.e.&nbsp;ChildPugh Class A and B). However, since plasma levels of pirfenidone may be increased in some individuals with mild to moderate hepatic impairment, caution should be used with Esbriet treatment in this population. Esbriet therapy should not be used in patients with severe hepatic impairment or end stage liver disease (see section 4.3, 4.4 and 5.2).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Renal impairment&nbsp;&nbsp;</strong></p><p dir="ltr"><strong>No dose adjustment is necessary in patients with mild to moderate renal impairment. Esbriet therapy should not be used in patients with severe renal impairment (CrCl &lt;30&nbsp;ml/min) or end stage renal disease requiring dialysis (see sections 4.3 and 5.2).&nbsp;&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Paediatric population&nbsp;</strong></p><p dir="ltr"><strong>There is no relevant use of Esbriet in the paediatric population for the indication of IPF.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Method of administration</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Esbriet is for oral use. The tablets are to be swallowed whole with water and taken with food to reduce the possibility of nausea and dizziness (see sections 4.8 and 5.2).</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
●	History of angioedema with pirfenidone (see section 4.4).
●	Concomitant use of fluvoxamine (see section 4.5).
●	Severe hepatic impairment or end stage liver disease (see sections 4.2 and 4.4).
●	Severe renal impairment (CrCl <30 ml/min) or end stage renal disease requiring dialysis (see 	sections 4.2 and 4.4).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Hepatic function</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Elevations in ALT and AST &gt;3&nbsp;&times;&nbsp;upper limit of normal (ULN) have been reported in patients receiving therapy with Esbriet. Rarely these have been associated with concomitant elevations in total serum bilirubin. Liver function tests (ALT, AST and bilirubin) should be conducted prior to the initiation of treatment with Esbriet, and subsequently at monthly intervals for the first 6&nbsp;months and then every 3&nbsp;months thereafter (see section 4.8). In the event of significant elevation of liver aminotransferases the dose of Esbriet should be adjusted or treatment discontinued according to the guidelines listed below. For patients with confirmed elevations in ALT, AST or bilirubin during treatment, the following dose adjustments may be necessary.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Recommendations in case of ALT/AST elevations</strong></p><p dir="ltr"><strong>If a patient exhibits an aminotransferase elevation to &gt;3&nbsp;to&nbsp;&le;5&nbsp;x&nbsp;ULN after starting Esbriet therapy, confounding medicinal products should be discontinued, other causes excluded, and the patient monitored closely. If clinically appropriate the dose of Esbriet should be reduced or interrupted. Once liver function tests are within normal limits Esbriet may be reescalated to the recommended daily dose if tolerated.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If a patient exhibits an aminotransferase elevation to &le;5&nbsp;x&nbsp;ULN accompanied by symptoms or hyperbilirubinaemia, Esbriet should be discontinued and the patient should not be rechallenged.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If a patient exhibits an aminotransferase elevation to &gt;5&nbsp;x&nbsp;ULN, Esbriet should be discontinued and the patient should not be rechallenged.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Hepatic impairment</strong></p><p dir="ltr"><strong>In subjects with moderate hepatic impairment (i.e. Child-Pugh Class B), pirfenidone exposure was increased by 60%. Esbriet should be used with caution in patients with preexisting mild to moderate hepatic impairment (i.e. Child-Pugh Class A and B) given the potential for increased pirfenidone exposure. Patients should be monitored closely for signs of toxicity especially if they are concomitantly taking a known CYP1A2 inhibitor (see sections 4.5 and 5.2). Esbriet has not been studied in individuals with severe hepatic impairment and Esbriet must not be used in patients with severe hepatic impairment (see section 4.3).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Photosensitivity reaction and rash</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Exposure to direct sunlight (including sunlamps) should be avoided or minimised during treatment with Esbriet. Patients should be instructed to use a sunblock daily, to wear clothing that protects against sun exposure, and to avoid other medicinal products known to cause photosensitivity. Patients should be instructed to report symptoms of photosensitivity reaction or rash to their physician. Severe photosensitivity reactions are uncommon. Dose adjustments or temporary treatment discontinuation may be necessary in mild to severe cases of photosensitivity reaction or rash (see section 4.2).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Angioedema</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Reports of angioedema (some serious) such as swelling of the face, lips and/or tongue which may be associated with difficulty breathing or wheezing have been received in association with use of Esbriet in the post-marketing setting. Therefore, patients who develop signs or symptoms of angioedema following administration of Esbriet should immediately discontinue treatment. Patients with angioedema should be managed according to standard of care. Esbriet must not be used in patients with a history of angioedema due to Esbriet (see section 4.3).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Dizziness</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Dizziness has been reported in patients taking Esbriet. Therefore, patients should know how they react to this medicinal product before they engage in activities requiring mental alertness or coordination (see section&nbsp;4.7). In clinical studies, most patients who experienced dizziness had a single event, and most events resolved, with a median duration of 22&nbsp;days. If dizziness does not improve or if it worsens in severity, dose adjustment or even discontinuation of Esbriet may be warranted.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Fatigue</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Fatigue has been reported in patients taking Esbriet. Therefore, patients should know how they react to this medicinal product before they engage in activities requiring mental alertness or coordination (see section&nbsp;4.7).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Weight loss</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Weight loss has been reported in patients treated with Esbriet (see section&nbsp;4.8). Physicians should monitor patient&rsquo;s weight, and when appropriate encourage increased caloric intake if weight loss is considered to be of clinical significance.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Approximately 70&ndash;80% of pirfenidone is metabolised via CYP1A2 with minor contributions from other CYP isoenzymes including CYP2C9, 2C19, 2D6, and 2E1.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Consumption of grapefruit juice is associated with inhibition of CYP1A2 and should be avoided during treatment with pirfenidone.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Fluvoxamine and inhibitors of CYP1A2</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In a Phase 1 study, the coadministration of Esbriet and fluvoxamine (a strong inhibitor of CYP1A2 with inhibitory effects on other CYP isoenzymes [CYP2C9, 2C19, and 2D6]) resulted in a 4fold increase in exposure to pirfenidone in non-smokers.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Esbriet is contraindicated in patients with concomitant use of fluvoxamine (see section 4.3).&nbsp; Fluvoxamine should be discontinued prior to the initiation of Esbriet therapy and avoided during Esbriet therapy due to the reduced clearance of pirfenidone. Other therapies that are inhibitors of both CYP1A2 and one or more other CYP isoenzymes involved in the metabolism of pirfenidone (e.g.&nbsp;CYP2C9, 2C19, and 2D6) should be avoided during pirfenidone treatment.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In vitro and in vivo extrapolations indicate that strong and selective inhibitors of CYP1A2 (e.g. enoxacin) have the potential to increase the exposure to pirfenidone by approximately 2 to 4-fold.&nbsp; If concomitant use of Esbriet with a strong and selective inhibitor of CYP1A2 cannot be avoided, the dose of pirfenidone should be reduced to 801 mg daily (267 mg, three times a day). Patients should be closely monitored for emergence of adverse reactions associated with Esbriet therapy. Discontinue Esbriet if necessary (see sections 4.2 and 4.4).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Co-administration of Esbriet and 750&nbsp;mg of ciprofloxacin (a moderate inhibitor of CYP1A2) increased the exposure to pirfenidone by 81%. If ciprofloxacin at the dose of 750&nbsp;mg two times a day cannot be avoided, the dose of pirfenidone should be reduced to 1602 mg daily (534 mg, three times a day). Esbriet should be used with caution when ciprofloxacin is used at a dose of 250&nbsp;mg or 500&nbsp;mg once or two times a day.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Esbriet should be used with caution in patients treated with other moderate inhibitors of CYP1A2 (e.g. amiodarone, propafenone).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Special care should also be exercised if CYP1A2 inhibitors are being used concomitantly with potent inhibitors of one or more other CYP isoenzymes involved in the metabolism of pirfenidone such as CYP2C9 (e.g. amiodarone, fluconazole), 2C19 (e.g. chloramphenicol) and 2D6 (e.g. fluoxetine, paroxetine).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Cigarette smoking and inducers of CYP1A2</strong></p><p>&nbsp;</p><p dir="ltr"><strong>A Phase 1 interaction study evaluated the effect of cigarette smoking (CYP1A2 inducer) on the pharmacokinetics of pirfenidone. The exposure to pirfenidone in smokers was 50% of that observed in non-smokers. Smoking has the potential to induce hepatic enzyme production and thus increase medicinal product clearance and decrease exposure. Concomitant use of strong inducers of CYP1A2 including smoking should be avoided during Esbriet therapy based on the observed relationship between cigarette smoking and its potential to induce CYP1A2. Patients should be encouraged to discontinue use of strong inducers of CYP1A2 and to stop smoking before and during treatment with pirfenidone.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In the case of moderate inducers of CYP1A2 (e.g. omeprazole), concomitant use may theoretically result in a lowering of pirfenidone plasma levels.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Coadministration of medicinal products that act as potent inducers of both CYP1A2 and the other CYP isoenzymes involved in the metabolism of pirfenidone (e.g. rifampicin) may result in significant lowering of pirfenidone plasma levels. These medicinal products should be avoided whenever possible.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Pregnancy</strong></p><p>&nbsp;</p><p dir="ltr"><strong>There are no data from the use of Esbriet in pregnant women.&nbsp;</strong></p><p dir="ltr"><strong>In animals placental transfer of pirfenidone and/or its metabolites occurs with the potential for accumulation of pirfenidone and/or its metabolites in amniotic fluid.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>At high doses (&ge;1,000&nbsp;mg/kg/day) rats exhibited prolongation of gestation and reduction in foetal viability.&nbsp;</strong></p><p dir="ltr"><strong>As a precautionary measure, it is preferable to avoid the use of Esbriet during pregnancy.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Breastfeeding</strong></p><p>&nbsp;</p><p dir="ltr"><strong>It is unknown whether pirfenidone or its metabolites are excreted in human milk. Available pharmacokinetic data in animals have shown excretion of pirfenidone and/or its metabolites in milk with the potential for accumulation of pirfenidone and/or its metabolites in milk (see section 5.3). A risk to the breastfed infant cannot be excluded.&nbsp;&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>A decision must be made whether to discontinue breastfeeding or to discontinue from Esbriet therapy, taking into account the benefit of breastfeeding for the child and the benefit of Esbriet therapy for the mother.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Fertility</strong></p><p>&nbsp;</p><p dir="ltr"><strong>No adverse effects on fertility were observed in preclinical studies (see section 5.3).</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><br /></p><p dir="ltr"><strong>Esbriet may cause dizziness and fatigue, which could have a moderate influence on the ability to drive or use machines, therefore patients should exercise caution when driving or operating machinery if they experience these symptoms.&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Summary of the safety profile</strong></p><p dir="ltr"><strong>The most frequently reported adverse reactions during clinical study experience with Esbriet at a dose of 2,403&nbsp;mg/day compared to placebo, respectively, were nausea (32.4% versus 12.2%), rash (26.2% versus 7.7%), diarrhoea (18.8% versus 14.4%), fatigue (18.5% versus 10.4%), dyspepsia (16.1% versus 5.0%), anorexia (11.4% versus 3.5%), headache (10.1% versus 7.7%), and photosensitivity reaction (9.3% versus 1.1%).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Tabulated list of adverse reactions</strong></p><p dir="ltr"><strong>The safety of Esbriet has been evaluated in clinical studies including 1,650 volunteers and patients. More than 170 patients have been investigated in open studies for more than five years and some for up to 10 years.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 1 shows the adverse reactions reported at a frequency of &ge;2% in 623 patients receiving Esbriet at the recommended dose of 2,403&nbsp;mg/day in three pooled pivotal Phase 3 studies. Adverse reactions from post-marketing experience are also listed in Table 1. Adverse reactions are listed by System Organ Class (SOC) and within each frequency grouping [Very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000)] the adverse reactions are presented in order of decreasing seriousness.</strong></p><p>&nbsp;</p><table><tbody><tr><td colspan="2"><p dir="ltr"><strong>Table 1 Adverse reactions by SOC and MedDRA frequency</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Infections and infestations</strong></p></td></tr><tr><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Upper respiratory tract infection; urinary tract infection</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Rare</strong></p></td><td><p dir="ltr"><strong>Agranulocytosis1</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Immune system disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Angioedema1</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Anorexia</strong></p></td></tr><tr><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Weight decreased; decreased appetite</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Psychiatric disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Insomnia</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Nervous system disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Headache</strong></p></td></tr><tr><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Dizziness; somnolence; dysgeusia; lethargy</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Vascular disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Hot flush</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Dyspnoea; cough; productive cough</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Dyspepsia; nausea; diarrhoea</strong></p></td></tr><tr><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Gastroesophageal reflux disease; vomiting; abdominal distension; abdominal discomfort; abdominal pain; abdominal pain upper; stomach discomfort; gastritis; constipation; flatulence</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>ALT increased; AST increased; gamma glutamyl transferase increased</strong></p></td></tr><tr><td><p dir="ltr"><strong>Rare</strong></p></td><td><p dir="ltr"><strong>Total serum bilirubin increased in combination with increases of ALT and AST1</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Photosensitivity reaction; rash&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Pruritus; erythema; dry skin; rash erythematous; rash macular; rash pruritic</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Myalgia; arthralgia&nbsp;</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Fatigue</strong></p></td></tr><tr><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Asthenia; non-cardiac chest pain</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Injury poisoning and procedural complications</strong></p></td></tr><tr><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Sunburn</strong></p></td></tr></tbody></table><p dir="ltr"><strong>1. Identified through post-marketing surveillance</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Reporting of suspected adverse reactions</strong></p><p dir="ltr"><strong>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions:&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>To reports any side effect(s):</strong><br />&nbsp;</p><p dir="ltr"><strong>&bull;&nbsp; &nbsp; Saudi Arabia:</strong><br />&nbsp;</p><table><tbody><tr><td><ul><li dir="ltr"><p dir="ltr"><strong>The National Pharmacovigilance and Drug Safety Centre (NPC)</strong></p></li></ul><ul><li dir="ltr"><p dir="ltr"><strong>Fax: +966-11-205-7662</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Toll free phone: 8002490000</strong></p></li><li dir="ltr"><p dir="ltr"><strong>E-mail: npc.drug@sfda.gov.sa</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Website: www.sfda.gov.sa/npc</strong></p></li></ul></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>&bull;&nbsp; &nbsp; Other GCC States:</strong><br />&nbsp;</p><table><tbody><tr><td><ul><li dir="ltr"><p dir="ltr"><strong>Please contact the relevant competent authority.</strong></p></li></ul></td></tr></tbody></table><p><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>There is limited clinical experience with overdose. Multiple doses of pirfenidone up to a total dose of 4,806&nbsp;mg/day were administered as six 267&nbsp;mg capsules three times daily to healthy adult volunteers over a 12day dose escalation period. Adverse reactions were mild, transient, and consistent with the most frequently reported adverse reactions for pirfenidone.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In the event of a suspected overdose, supportive medical care should be provided including monitoring of vital signs and close observation of the clinical status of the patient.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Pharmacotherapeutic group: Immunosuppressants, other immunosuppressants, ATC code:&nbsp; L04AX05</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The mechanism of action of pirfenidone has not been fully established. However, existing data suggest that pirfenidone exerts both antifibrotic and antiinflammatory properties in a variety of in vitro systems and animal models of pulmonary fibrosis (bleomycin- and transplantinduced fibrosis).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>IPF is a chronic fibrotic and inflammatory pulmonary disease affected by the synthesis and release of proinflammatory cytokines including tumour necrosis factor-alpha (TNF&alpha;) and interleukin1beta (IL1&beta;) and pirfenidone has been shown to reduce the accumulation of inflammatory cells in response to various stimuli.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pirfenidone attenuates fibroblast proliferation, production of fibrosis-associated proteins and cytokines, and the increased biosynthesis and accumulation of extracellular matrix in response to cytokine growth factors such as, transforming growth factor-beta (TGF&beta;) and platelet-derived growth factor (PDGF).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Clinical efficacy</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The clinical efficacy of Esbriet has been studied in four Phase 3, multicentre, randomised, doubleblind, placebocontrolled studies in patients with IPF. Three of the Phase 3 studies (PIPF004, PIPF006, and PIPF-016) were multinational, and one (SP3) was conducted in Japan.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>PIPF004 and PIPF006 compared treatment with Esbriet 2403&nbsp;mg/day to placebo. The studies were nearly identical in design, with few exceptions including an intermediate dose group (1,197&nbsp;mg/day) in PIPF004. In both studies, treatment was administered three times daily for a minimum of 72&nbsp;weeks. The primary endpoint in both studies was the change from Baseline to Week&nbsp;72 in percent predicted Forced Vital Capacity (FVC).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In study PIPF004, the decline of percent predicted FVC from Baseline at Week&nbsp;72 of treatment was significantly reduced in patients receiving Esbriet (N=174) compared with patients receiving placebo (N=174; p=0.001, rank ANCOVA). Treatment with Esbriet also significantly reduced the decline of percent predicted FVC from Baseline at Weeks&nbsp;24 (p=0.014), 36&nbsp;(p&lt;0.001), 48 (p&lt;0.001), and 60&nbsp;(p&lt;0.001). At Week&nbsp;72, a decline from baseline in percent predicted FVC of &ge;10% (a threshold indicative of the risk of mortality in IPF) was seen in 20% of patients receiving Esbriet compared to 35% receiving placebo (Table 2).&nbsp;</strong></p><p>&nbsp;</p><table><tbody><tr><td colspan="3"><p dir="ltr"><strong>Table 2 Categorical assessment of change from Baseline to Week 72 in percent predicted FVC in study PIPF-004</strong></p></td></tr><tr><td>&nbsp;</td><td><p dir="ltr"><strong>Pirfenidone<br />2,403&nbsp;mg/day<br />(N&nbsp;=&nbsp;174)</strong></p></td><td><p dir="ltr"><strong>Placebo<br />(N&nbsp;=&nbsp;174)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Decline of &ge;10% or death or lung transplant</strong></p></td><td><p dir="ltr"><strong>35 (20%)</strong></p></td><td><p dir="ltr"><strong>60 (34%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Decline of less than 10%</strong></p></td><td><p dir="ltr"><strong>97 (56%)</strong></p></td><td><p dir="ltr"><strong>90 (52%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>No decline (FVC change &gt;0%)</strong></p></td><td><p dir="ltr"><strong>42 (24%)</strong></p></td><td><p dir="ltr"><strong>24 (14%)</strong></p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>Although there was no difference between patients receiving Esbriet compared to placebo in change from Baseline to Week&nbsp;72 of distance walked during a six minute walk test (6MWT) by the prespecified rank ANCOVA, in an ad hoc analysis, 37% of patients receiving Esbriet showed a decline of &ge;50&nbsp;m in 6MWT distance, compared to 47% of patients receiving placebo in PIPF-004.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In study PIPF006, treatment with Esbriet (N=171) did not reduce the decline of percent predicted FVC from Baseline at Week&nbsp;72 compared with placebo (N=173; p=0.501). However, treatment with Esbriet reduced the decline of percent predicted FVC from Baseline at Weeks&nbsp;24 (p&lt;0.001), 36&nbsp;(p=0.011), and 48 (p=0.005). At Week&nbsp;72, a decline in FVC of &ge;10% was seen in 23% of patients receiving Esbriet and 27% receiving placebo (Table 3).&nbsp;</strong></p><p>&nbsp;</p><table><tbody><tr><td colspan="3"><p dir="ltr"><strong>Table 3 Categorical assessment of change from Baseline to Week 72 in percent predicted FVC in study PIPF-006</strong></p></td></tr><tr><td>&nbsp;</td><td><p dir="ltr"><strong>Pirfenidone<br />2,403&nbsp;mg/day<br />(N&nbsp;=&nbsp;171)</strong></p></td><td><p dir="ltr"><strong>Placebo<br />(N&nbsp;=&nbsp;173)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Decline of &ge;10% or death or lung transplant</strong></p></td><td><p dir="ltr"><strong>39 (23%)</strong></p></td><td><p dir="ltr"><strong>46 (27%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Decline of less than 10%</strong></p></td><td><p dir="ltr"><strong>88 (52%)</strong></p></td><td><p dir="ltr"><strong>89 (51%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>No decline (FVC change &gt;0%)</strong></p></td><td><p dir="ltr"><strong>44 (26%)</strong></p></td><td><p dir="ltr"><strong>38 (22%)</strong></p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>The decline in 6MWT distance from Baseline to Week&nbsp;72 was significantly reduced compared with placebo in study PIPF-006 (p&lt;0.001, rank ANCOVA). Additionally, in an ad hoc analysis, 33% of patients receiving Esbriet showed a decline of &ge;50&nbsp;m in 6MWT distance, compared to 47% of patients receiving placebo in PIPF-006.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In a pooled analysis of survival in PIPF004 and PIPF006 the mortality rate with Esbriet 2403&nbsp;mg/day group was 7.8% compared with 9.8% with placebo (HR 0.77 [95% CI, 0.47&ndash;1.28]).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>PIPF-016 compared treatment with Esbriet 2,403 mg/day to placebo. Treatment was administered three times daily for 52 weeks. The primary endpoint was the change from Baseline to Week 52 in percent predicted FVC. In a total of 555 patients, the median baseline percent predicted FVC and %DLCO were 68% (range: 48&ndash;91%) and 42% (range: 27&ndash;170%), respectively. Two percent of patients had percent predicted FVC below 50% and 21% of patients had a percent predicted DLCO below 35% at Baseline.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In study PIPF-016, the decline of percent predicted FVC from Baseline at Week 52 of treatment was significantly reduced in patients receiving Esbriet (N=278) compared with patients receiving placebo (N=277; p&lt;0.000001, rank ANCOVA). Treatment with Esbriet also significantly reduced the decline of percent predicted FVC from Baseline at Weeks 13 (p&lt;0.000001), 26 (p&lt;0.000001), and 39 (p=0.000002). At Week 52, a decline from Baseline in percent predicted FVC of &ge;10% or death was seen in 17% of patients receiving Esbriet compared to 32% receiving placebo (Table 4).</strong></p><p>&nbsp;</p><table><tbody><tr><td colspan="3"><p dir="ltr"><strong>Table 4 Categorical assessment of change from Baseline to Week 52 in percent predicted FVC in study PIPF-016</strong></p></td></tr><tr><td>&nbsp;</td><td><p dir="ltr"><strong>Pirfenidone<br />2,403&nbsp;mg/day<br />(N&nbsp;=&nbsp;278)</strong></p></td><td><p dir="ltr"><strong>Placebo<br />(N&nbsp;=&nbsp;277)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Decline of &ge;10% or death</strong></p></td><td><p dir="ltr"><strong>46 (17%)</strong></p></td><td><p dir="ltr"><strong>88 (32%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Decline of less than 10%</strong></p></td><td><p dir="ltr"><strong>169 (61%)</strong></p></td><td><p dir="ltr"><strong>162 (58%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>No decline (FVC change &gt;0%)</strong></p></td><td><p dir="ltr"><strong>63 (23%)</strong></p></td><td><p dir="ltr"><strong>27 (10%)</strong></p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>The decline in distance walked during a 6MWT from Baseline to Week 52 was significantly reduced in patients receiving Esbriet compared with patients receiving placebo in PIPF-016 (p=0.036, rank ANCOVA); 26% of patients receiving Esbriet showed a decline of &ge;50 m in 6MWT distance compared to 36% of patients receiving placebo.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In a pre-specified pooled analysis of studies PIPF-016, PIPF-004, and PIPF-006 at Month 12, allcause mortality was significantly lower in Esbriet 2403 mg/day group (3.5%, 22 of 623 patients) compared with placebo (6.7%, 42 of 624 patients), resulting in a 48% reduction in the risk of all-cause mortality within the first 12 months (HR 0.52 [95% CI, 0.31&ndash;0.87], p=0.0107, log-rank test).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The study (SP3) in Japanese patients compared pirfenidone 1800&nbsp;mg/day (comparable to 2403&nbsp;mg/day in the US and European populations of PIPF004/006 on a weightnormalised basis) with placebo (N=110, N=109, respectively). Treatment with pirfenidone significantly reduced mean decline in vital capacity (VC) at Week&nbsp;52 (the primary endpoint) compared with placebo (0.09&plusmn;0.02&nbsp;l versus 0.16&plusmn;0.02&nbsp;l respectively, p=0.042).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Paediatric population</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The European Medicines Agency has waived the obligation to submit the results of studies with Esbriet in all subsets of the paediatric population in IPF (see section&nbsp;4.2 for information on paediatric use).</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Absorption</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Administration of Esbriet capsules with food results in a large reduction in Cmax (by 50%) and a smaller effect on AUC, compared to the fasted state. Following oral administration of a single dose of 801&nbsp;mg to healthy older adult volunteers (5066 years of age) in the fed state, the rate of pirfenidone absorption slowed, while the AUC in the fed state was approximately 8085% of the AUC observed in the fasted state. Bioequivalence was demonstrated in the fasted state when comparing the 801 mg tablet to three 267 mg capsules. In the fed state, the 801 mg tablet met bioequivalence criteria based on the AUC measurements compared to the capsules, while the 90% confidence intervals for Cmax (108.26% - 125.60%) slightly exceeded the upper bound of standard bioequivalence limit (90% CI:&nbsp; 80.00% - 125.00%). The effect of food on pirfenidone oral AUC was consistent between the tablet and capsule formulations. Compared to the fasted state, administration of either formulation with food reduced pirfenidone Cmax, with Esbriet tablet reducing the Cmax slightly less (by 40%) than Esbriet capsules (by 50%). A reduced incidence of adverse events (nausea and dizziness) was observed in fed subjects when compared to the fasted group. Therefore, it is recommended that Esbriet be administered with food to reduce the incidence of nausea and dizziness.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The absolute bioavailability of pirfenidone has not been determined in humans.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Distribution</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pirfenidone binds to human plasma proteins, primarily to serum albumin. The overall mean binding ranged from 50% to 58% at concentrations observed in clinical studies (1&nbsp;to&nbsp;100&nbsp;&mu;g/ml). Mean apparent oral steady-state volume of distribution is approximately 70&nbsp;l, indicating that pirfenidone distribution to tissues is modest.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Biotransformation</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Approximately 70&ndash;80% of pirfenidone is metabolised via CYP1A2 with minor contributions from other CYP isoenzymes including CYP2C9, 2C19, 2D6, and 2E1. In vitro and in vivo studies to date have not detected any activity of the major metabolite (5carboxy-pirfenidone), even at concentrations or doses greatly above those associated with activity of pirfenidone itself.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Elimination&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The oral clearance of pirfenidone appears modestly saturable. In a multipledose, doseranging study in healthy older adults administered doses ranging from 267&nbsp;mg to 1,335&nbsp;mg three times a day, the mean clearance decreased by approximately 25% above a dose of 801&nbsp;mg three times a day. Following single dose administration of pirfenidone in healthy older adults, the mean apparent terminal elimination halflife was approximately 2.4&nbsp;hours. Approximately 80% of an orally administered dose of pirfenidone is cleared in the urine within 24&nbsp;hours of dosing. The majority of pirfenidone is excreted as the 5carboxy-pirfenidone metabolite (&gt;95% of that recovered), with less than 1% of pirfenidone excreted unchanged in urine.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Special populations</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Hepatic impairment</strong></p><p dir="ltr"><strong>The pharmacokinetics of pirfenidone and the 5carboxy-pirfenidone metabolite were compared in subjects with moderate hepatic impairment (ChildPugh Class B) and in subjects with normal hepatic function. Results showed that there was a mean increase of 60% in pirfenidone exposure after a single dose of 801&nbsp;mg pirfenidone (3&nbsp;x&nbsp;267&nbsp;mg capsule) in patients with moderate hepatic impairment. Pirfenidone should be used with caution in patients with mild to moderate hepatic impairment and patients should be monitored closely for signs of toxicity especially if they are concomitantly taking a known CYP1A2 inhibitor (see sections 4.2 and 4.4). Esbriet is contraindicated in severe hepatic impairment and end stage liver disease (see&nbsp;sections 4.2 and 4.3).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Renal impairment</strong></p><p dir="ltr"><strong>No clinically relevant differences in the pharmacokinetics of pirfenidone were observed in subjects with mild to severe renal impairment compared with subjects with normal renal function. The parent substance is predominantly metabolised to 5carboxy-pirfenidone, and the pharmacokinetics of this metabolite is altered in subjects with moderate to severe renal impairment. However, the predicted amount of metabolite accumulation at steady state is not pharmacodynamically important because the terminal elimination halflife is only 1&ndash;2 hours in these subjects. No dose adjustment is required in patients with mild to moderate renal impairment who are receiving pirfenidone. The use of pirfenidone is contraindicated in patients with severe renal impairment (CrCl&nbsp;&lt;30ml/min) or end stage renal disease requiring dialysis (see sections 4.2 and 4.3).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Population pharmacokinetic analyses from 4 studies in healthy subjects or subjects with renal impairment and one study in patients with IPF showed no clinically relevant effect of age, gender or body size on the pharmacokinetics of pirfenidone.&nbsp;</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In repeated dose toxicity studies increases in liver weight were observed in mice, rats and dogs; this was often accompanied by hepatic centrilobular hypertrophy. Reversibility was observed after cessation of treatment. An increased incidence of liver tumours was observed in carcinogenicity studies conducted in rats and mice. These hepatic findings are consistent with an induction of hepatic microsomal enzymes, an effect which has not been observed in patients receiving Esbriet. These findings are not considered relevant to humans.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>A statistically significant increase in uterine tumours was observed in female rats administered 1,500&nbsp;mg/kg/day, 37&nbsp;times the human dose of 2,403&nbsp;mg/day. The results of mechanistic studies indicate that the occurrence of uterine tumours is probably related to a chronic dopamine-mediated sex hormone imbalance involving a species specific endocrine mechanism in the rat which is not present in humans.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Reproductive toxicology studies demonstrated no adverse effects on male and female fertility or postnatal development of offspring in rats and there was no evidence of teratogenicity in rats (1,000&nbsp;mg/kg/day) or rabbits (300&nbsp;mg/kg/day). In animals placental transfer of pirfenidone and/or its metabolites occurs with the potential for accumulation of pirfenidone and/or its metabolites in amniotic fluid. At high doses (&ge;450&nbsp;mg/kg/day) rats exhibited a prolongation of oestrous cycle and a high incidence of irregular cycles. At high doses (&ge;1,000&nbsp;mg/kg/day) rats exhibited a prolongation of gestation and reduction in fetal viability. Studies in lactating rats indicate that pirfenidone and/or its metabolites are excreted in milk with the potential for accumulation of pirfenidone and/or its metabolites in milk.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pirfenidone showed no indication of mutagenic or genotoxic activity in a standard battery of tests and when tested under UV exposure was not mutagenic. When tested under UV exposure pirfenidone was positive in a photoclastogenic assay in Chinese hamster lung cells.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Phototoxicity and irritation were noted in guinea pigs after oral administration of pirfenidone and with exposure to UVA/UVB light. The severity of phototoxic lesions was minimised by application of sunscreen.&nbsp;&nbsp;</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Tablet core</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Microcrystalline cellulose</strong></p><p dir="ltr"><strong>Croscarmellose sodium</strong></p><p dir="ltr"><strong>Povidone K30</strong></p><p dir="ltr"><strong>Colloidal anhydrous silica</strong></p><p dir="ltr"><strong>Magnesium stearate</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Film coat&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Polyvinyl alcohol</strong></p><p dir="ltr"><strong>Titanium dioxide (E171)</strong></p><p dir="ltr"><strong>Macrogol 3350</strong></p><p dir="ltr"><strong>Talc</strong></p><p dir="ltr"><strong>267 mg tablet</strong></p><p dir="ltr"><strong>Iron oxide yellow (E172)&nbsp;</strong></p><p dir="ltr"><strong>534 mg tablet</strong></p><p dir="ltr"><strong>Iron oxide yellow (E172)</strong></p><p dir="ltr"><strong>Iron oxide red (E172)&nbsp;</strong></p><p dir="ltr"><strong>801 mg tablet</strong></p><p dir="ltr"><strong>Iron oxide red (E172)&nbsp;</strong></p><p dir="ltr"><strong>Iron oxide black (E172)&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Not applicable.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>This medicinal product does not require any special storage conditions.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>High-Density Polyethylene (HDPE) bottle with a child-resistant and tamper-evident screw cap</strong></p><p dir="ltr"><strong>Pack sizes</strong></p><p>&nbsp;</p><p dir="ltr"><strong>267 mg film-coated tablets</strong></p><p dir="ltr"><strong>1 bottle containing 21 film-coated tablets</strong></p><p dir="ltr"><strong>2 bottles each containing 21 film-coated tablets (42 film-coated tablets in total)</strong></p><p dir="ltr"><strong>1 bottle containing 90 film-coated tablets</strong></p><p dir="ltr"><strong>2 bottles each containing 90 film-coated tablets (180 film-coated tablets in total)</strong></p><p>&nbsp;</p><p dir="ltr"><strong>534 mg film-coated tablets</strong></p><p dir="ltr"><strong>1 bottle containing 21 film-coated tablets</strong></p><p dir="ltr"><strong>1 bottle containing 90 film-coated tablets</strong></p><p>&nbsp;</p><p dir="ltr"><strong>801 mg film-coated tablets</strong></p><p dir="ltr"><strong>1 bottle containing 90 film-coated tablets</strong></p><p>&nbsp;</p><p dir="ltr"><strong>PVC/Aclar (PCTFE) aluminium foil blister Pack sizes<br />267 mg film-coated tablets<br /><br />1 blister containing 21 film-coated tablets (21 in total)<br />2 blisters each containing 21 film-coated tablets (42 in total)<br />4 blisters each containing 21 film-coated tablets (84 in total)<br />8 blisters each containing 21 Film-coated tablets (168 in total)<br /><br />2-week treatment initiation pack: multipack containing 63 (1 pack containing 1 blister of 21 and 1 pack containing 2 blisters of&nbsp; 21) film-coated tablets<br /><br />Continuation pack: multipack containing 252 (3 packs each containing 4 blisters of 21) film-coated tablets<br /><br />801 mg film-coated tablets<br /><br />4 blisters each containing 21 film-coated tablets (84 in total)</strong><br />&nbsp;</p><p dir="ltr"><strong>Continuation pack: multipack containing 252 (3 packs each containing 4 blisters of 21) film-coated tablets</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Not all pack sizes may be marketed.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                F. Hoffmann-La Roche Ltd,
Grenzacherstrasse 124, 
CH-4070 Basel, 
Switzerland.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 April 2017

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>